Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.

Date publication

novembre 2011

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François , Pr CORMIER Luc , Dr MIRJOLET Céline

Tous les auteurs :
Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21605949

Résumé

PURPOSE: To investigate the time course response of prostate metabolism to irradiation using magnetic resonance spectroscopy (MRS) at 3-month intervals and its impact on biochemical control. METHODS AND MATERIALS: Between January 2008 and April 2010, 24 patients with localized prostate cancer were prospectively enrolled in the Evaluation of the Response to Irradiation with MR Spectroscopy (ERIS) trial. All the patients had been treated with intensity-modulated radiation therapy with or without long-term adjuvant hormonal therapy (LTHT) and underwent 3-T MRS and prostate-specific antigen (PSA) assays at baseline and every 3 months thereafter up to 12 months. RESULTS: After radiation, the mean normalized citrate level (citrate/water) decreased significantly over time, both in the peripheral zone (PZ) (p = 0.0034) and in the entire prostate (p = 0.0008), whereas no significant change was observed in mean normalized choline levels (choline/water) in the PZ (p = 0.84) and in the entire prostate (p = 0.95). At 6 months after radiation, the mean choline level was significantly lower in the PZ for patients with a PSA value of

Référence

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e407-13